Publications

Journal Article Ahead of print

PubMed: 42931748 DOI: 10.1001/jama.2026.18107

Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.

JAMA

Authors: Francesco Giorgino, Lisa Ludwig, Max Denning

Affiliations

  • Department of Regenerative and Precision Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
  • Eli Lilly and Company, Indianapolis, Indiana.

MeSH

Diabetes Mellitus, Risk Assessment, Diabetes Mellitus, Type 2